Clinical Outcomes of Systemic Chemotherapy in Patients with High Grade Neuroendocrine Carcinoma of Biliary Tract Abstract #1773

Introduction: : Neuroendocarine tumor of biliary tract is very rare and clinical outcomes of advanced neuroendocrine tumors of biliary tract has not been well demonstrated.
Aim(s): We retrospectively analyze the treatment outcomes of systemic chemotherapy in patients with neuroendocrine tumor of biliary tract.
Materials and methods: Between January 2012 and October 2014, 8 patients with neuroendocrine tumor of biliary tract who received systemic chemotherapy were identified and included. Baseline clinicopathologic characteristics and clinical outcomes were retrospectively reviewed.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: MD Changhoon Yoo

To read results and conclusion, please login ...

Further abstracts you may be interested in

#41 Immunohisochemical evaluation of EMT regulators, E- and N-cadherin in neuroendocrine Tumors of the Gastro-Entero-Pancreativ system
Introduction: Local tumor invasion represents the first step of the metastatic cascade of carcinomas, and requires changes in cell adhesion and migration properties of tumor cells. This biologic process is known as epithelial-mesenchymal transition (EMT). One key biochemical change associated with EMT is the loss of E-cadherin expression promoted by specific transcriptional repressors such as Snail, Slug, and Twist. Overexpression of EMT inducers increases other factors, such as FoxC2, although its role in EMT is poorly understood. Neuroendocrine tumors (NETs) of the gastroenteropancreatic (GEP) system, originated from the diffuse endocrine system, represent a heterogeneous group of tumors. Their prevalence has increased substantially over the past three decades, without substantial improvements in their clinical management, and their variable clinical course cannot be predicted by common clinicopathological parameters. Thus, new prognostic markers are urgently needed.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: JOSE A. GALVÁN
#62 Genome-wide DNA methylation profiling of pancreatic neuroendocrine tumors identifies distinct methylation profiles and differentially methylated gene promoter regions associated with low, medium and high grade tumors
Introduction: Integration of genetics and epigenetics has emerged as a powerful approach to studying cellular differentiation (Mikkelsen et al, 2009) and tumorigenesis (Shen et al, 2007). The study of DNA methylation is of particular importance in cancer, as causal involvement has been demonstrated and it is the most stable of all epigenetic modifications, making it a desirable marker for both early detection and treatment of tumors. Hypermethylation of CpG sites in gene promoter regions leads to decreased gene expression; if such a gene is a tumor suppressor, this leads to carcinogenesis. To date, there have been no studies of genome-wide DNA methylation profiling of NETs. This study sets out to determine the DNA methylation profiles of low, intermediate and high grade pancreatic NET liver metastases with the intention of identifying dysregulated biological pathways in the development of these tumors. A protocol for the analysis formalin-fixed paraffin embedded tissue (FFPE) has also been developed in order to study these tumors in significant numbers following this pilot study.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Christina Thirlwell
#67 Interest of combined chromogranin A and pancreatic polypeptide for diagnosis and follow-up of gastroenteropancreatic endocrine carcinoma
Introduction: Assessment of tumor burden changes is essential for the management of well-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEPNET). Chromogranin A (CgA) is the principal tumor marker for such tumors; however, its use to evaluate morphological tumor progression is not validated. Combined CgA and pancreatic polypeptide (PP) may increase sensitivity in the diagnosis of GEP-NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Thomas WALTER
#90 The prognostic value of FDG-PET scan in neuroendocrine tumors: a retrospective analysis of 46 patients treated in one center
Introduction: Neuroendocrine tumors (NETs) are rare and generally indolent. For diagnostic purposes, the sensitivity of FDG-PET scan is known to be low in this setting, though when positive, its prognostic value is not well-defined in NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Ivan Borbath
#103 From hormone dependent solid breast carcinoma to primary neuroendocrine carcinoma: a case report
Introduction: Primary neuroendocrine carcinoma of the breast is an extremely rare tumor with incidence of 0.27-0.5%.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Djuro P Macut
Authors: Macut D, Kecman G, Bogavac T, Popovic B, ...